中銀人壽上半年NBV升84% 人壽保險市佔率踞首
中銀人壽宣布2022上半年業績穩步上揚。截至2022年6月30日止,公司新造標準保費為66.04億港元 ,按年同期升5.1%。上半年新業務價值(NBV)達9.64億港元,較去年同期大幅上升84%,以新造標準保費計算,市佔率由去年同期14.7%提升至21.2%,令中銀人壽業務續踞本港人壽保險市場首位。
中銀人壽執行總裁鄧子平稱,未來會繼續優化業務結構,加速數字化轉型並深化多渠道策略。此外,公司將進一步拓展保險加跨行業的夥伴合作,建立退休養老、大健康、ESG以及教育主題的業務生態圈,推出更多專業認證的綠色保險產品,增加資源發展綠色金融,也為日後經濟復甦時迅速把握大灣區的業務機遇做好準備。
根據保險業監管局剛公布2022年上半年保險業臨時統計數字,期內長期業務的新造保單保費(不包括退休計劃)為819億港元,整體按年升1.7%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.